Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
about
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyTargeted delivery of platinum-taxane combination therapy in ovarian cancer.Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity.Peritonectomy HIPEC-contemporary results, indications.Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach.
P2860
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
@ast
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
@en
type
label
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
@ast
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
@en
prefLabel
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
@ast
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.
@en
P2093
P2860
P356
P1476
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy
@en
P2093
Archana Rao
David L Morris
Terence C Chua
P2860
P304
P356
10.2147/CMAR.S31070
P407
P577
2012-11-23T00:00:00Z